SP-420 for iron overload in certain blood disorders
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests SP-420 to help people with transfusion-related iron overload from either beta-thalassemia or low-risk myelodysplastic syndromes. It aims to see if the treatment can improve how the body handles excess iron, which builds up after repeated transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- You have transfusion-dependent beta-thalassemia or low-risk myelodysplastic syndrome (MDS)
- You have iron overload from transfusions (your iron levels are high enough for the study)
- You’ve been on stable iron-chelation treatment for at least 4 weeks (for thalassemia) or have been followed at an MDS-experienced clinic for at least 6 months
- Your weight is at least 35 kg
- You can complete required study checks, including MRI if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This trial tests a new way to remove extra iron from the blood using a machine (like dialysis). It is for people with myelodysplastic syndrome or myelofibrosis who have severe anemia, high iron levels, and cannot take standard iron-removal pills or injections.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
Hear when a new Beta Thalassemia Major Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.